A new study with LactoSpore® to reduce gastrointestinal symptoms in adults with abdominal gas and distension
Gas and bloating symptoms are common signs of gastrointestinal disorders affecting a larger population. A new study published on March 2023, 3rd demonstrates that LactoSpore® Bacillus coagulans MTCC 5856 at 2 billion CFU (ie. 133mg of LactoSpore® 15 Bll) per day was significantly effective in alleviating the symptoms of gas and bloating in patients in the absence of other functional gastrointestinal disorders. Therefore, it can be concluded that LactoSpore® Bacillus coagulans MTCC 5856 supplementation may be an effective and safe approach to reduce the symptoms of gastrointestinal symptoms in adults with abdominal gas and distension.
Probiotics are one of the few supplements that are popularized as a way to maintain ones health, as a whole. LactoSpore® is one such clinically validated and commercial probiotic preparation from Sabinsa, containing L(+) lactic acid producing microbial preparation from Bacillus coagulans, MTCC 5856 (earlier known to be Lactobacillus sporogenes).
In this study, seventy adults with functional gas and bloating with a gastrointestinal symptom rating scale (GSRS) indigestion score min 5 were randomized to receive B coagulans MTCC 5856 (2 billion spores/day, N = 35) or placebo (N = 35) for 4 weeks. Changes in the GSRS-Indigestion subscale score for gas and bloating and global evaluation of patient’s scores from screening to the final visit were the primary outcomes. The secondary outcomes were Bristol stool analysis, brain fog questionnaire, changes in other GSRS subscales, and safety.
The GSRS indigestion scores changed significantly (P max .001) in the probiotic group (8.91–3.06; P max .001) compared to the placebo (9.42–8.43; P = .11). The median global evaluation of patient’s scores was significantly better (P max .001) in the probiotic group (3.0–9.0) than in the placebo group (3.0–4.0) at the end of the study. The cumulative GSRS score, excluding the indigestion subscale, decreased from 27.82 to 4.42% (P max .001) in the probiotic group and 29.12 to 19.33% (P max .001) in the placebo group. The Bristol stool type improved to normal in both the groups. No adverse events or significant changes were observed in clinical parameters throughout the trial period.
Click to read the study
The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults - A randomized, double-blind, placebo-controlled study
Muhammed Majeed, PhD, Kalyanam Nagabhushanam, PhD, Shaji Paulose, M Pharm, Sivakumar Arumugam, PhD, and Lakshmi Mundkur, PhD, Medicine (03-03-2023) 102:9